ATE442148T1 - Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren - Google Patents
Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatorenInfo
- Publication number
- ATE442148T1 ATE442148T1 AT02715273T AT02715273T ATE442148T1 AT E442148 T1 ATE442148 T1 AT E442148T1 AT 02715273 T AT02715273 T AT 02715273T AT 02715273 T AT02715273 T AT 02715273T AT E442148 T1 ATE442148 T1 AT E442148T1
- Authority
- AT
- Austria
- Prior art keywords
- combination therapy
- retinoid
- receptor modulators
- absorption inhibitors
- glucose absorption
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
- 102000034527 Retinoid X Receptors Human genes 0.000 title 1
- 108010038912 Retinoid X Receptors Proteins 0.000 title 1
- 238000010521 absorption reaction Methods 0.000 title 1
- 239000008103 glucose Substances 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000030558 renal glucose absorption Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28147901P | 2001-04-04 | 2001-04-04 | |
PCT/US2002/010542 WO2002080935A1 (en) | 2001-04-04 | 2002-04-03 | Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE442148T1 true ATE442148T1 (de) | 2009-09-15 |
Family
ID=23077475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02715273T ATE442148T1 (de) | 2001-04-04 | 2002-04-03 | Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren |
Country Status (11)
Country | Link |
---|---|
US (3) | US6838442B2 (de) |
EP (1) | EP1392326B1 (de) |
JP (1) | JP4590158B2 (de) |
CN (1) | CN100384430C (de) |
AT (1) | ATE442148T1 (de) |
CA (1) | CA2443325C (de) |
DE (1) | DE60233655D1 (de) |
ES (1) | ES2331561T3 (de) |
MY (1) | MY148432A (de) |
TW (1) | TWI345978B (de) |
WO (1) | WO2002080935A1 (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60022207T2 (de) | 1999-08-31 | 2006-06-22 | Incyte San Diego Incorporated, San Diego | Benzyliden-thiazolidindione und analoga und ihre verwendung zur behandlung von diabetes |
AU2002252227A1 (en) | 2001-03-07 | 2002-09-24 | Maxia Pharmaceuticals, Inc. | Heterocyclic derivatives for the treatment of cancer and other proliferative diseases |
EP1377559A4 (de) | 2001-03-08 | 2005-09-28 | Incyte San Diego Inc | Rxr-aktivierende moleküle |
CN100577175C (zh) * | 2001-04-04 | 2010-01-06 | 奥索-麦克尼尔药品公司 | 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法 |
NZ519403A (en) * | 2001-06-21 | 2005-03-24 | Pfizer Prod Inc | Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels |
JP2005513026A (ja) * | 2001-11-15 | 2005-05-12 | インサイト サン ディエゴ インコーポレイテッド | 高コレステロール血症、異脂肪血症および他の代謝障害;癌、および他の疾患を治療するn−置換複素環 |
US7102000B2 (en) | 2002-03-08 | 2006-09-05 | Incyte San Diego Inc. | Heterocyclic amide derivatives for the treatment of diabetes and other diseases |
US7196108B2 (en) * | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
DE10258007B4 (de) * | 2002-12-12 | 2006-02-09 | Sanofi-Aventis Deutschland Gmbh | Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
DE10258008B4 (de) * | 2002-12-12 | 2006-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel |
RU2005140949A (ru) * | 2003-06-27 | 2007-08-10 | Д-р Редди`с Ресерч Фаундэйшн (IN) | Композиции, включающие балаглитазон и дополнительные противодиабетические соединения |
CN1319956C (zh) * | 2003-09-12 | 2007-06-06 | 深圳市海粤门生物科技开发有限公司 | 一种噻唑烷二酮的衍生物及其药用制剂的制备方法和应用 |
NZ550340A (en) * | 2004-03-17 | 2010-08-27 | Lars Michael Larsen | Prevention of retinopathy by inhibition of the visual cycle using a retinoid |
DE102006028862A1 (de) | 2006-06-23 | 2007-12-27 | Merck Patent Gmbh | 3-Amino-imidazo[1,2-a]pyridinderivate |
DE102007008420A1 (de) | 2007-02-21 | 2008-08-28 | Merck Patent Gmbh | Benzimidazolderivate |
DE102007048716A1 (de) | 2007-10-11 | 2009-04-23 | Merck Patent Gmbh | Imidazo[1,2-a]pyrimidinderivate |
KR101516677B1 (ko) * | 2008-01-31 | 2015-05-04 | 고토부키 세이야쿠 가부시키가이샤 | 지방성 간 질환의 치료용 의약 조성물 |
DE102008017590A1 (de) | 2008-04-07 | 2009-10-08 | Merck Patent Gmbh | Glucopyranosidderivate |
JP5820269B2 (ja) | 2008-05-22 | 2015-11-24 | アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag | Sglt2阻害剤を使用する高尿酸血症の治療方法およびsglt2阻害剤を含有する組成物 |
PT2334687E (pt) | 2008-08-28 | 2012-04-13 | Pfizer | Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol |
WO2010141690A2 (en) * | 2009-06-04 | 2010-12-09 | Dara Biosciences, Inc. | Indane analogs and use as pharmaceutical agents and process of making |
US8163704B2 (en) | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
KR101426180B1 (ko) | 2009-11-02 | 2014-07-31 | 화이자 인코포레이티드 | 디옥사-비시클로[3.2.1]옥탄-2,3,4-트리올 유도체 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
CA2935334C (en) | 2013-01-18 | 2021-05-25 | Cornell University | Methods of treating diseases associated with high fat diet and vitamin a deficiency using retinoic acid receptor agonists |
EP2774619B1 (de) | 2013-03-04 | 2016-05-18 | BioActive Food GmbH | Zusammensetzung zur Behandlung von hyperglykämischen Erkrankungen |
EP2944311A1 (de) | 2014-05-16 | 2015-11-18 | BioActive Food GmbH | Kombination von biologisch aktiven Substanzen zur Behandlung von hyperglykämischen Erkrankungen |
CR20210029A (es) | 2018-07-19 | 2021-02-26 | Astrazeneca Ab | MÉTODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA |
TW202220672A (zh) | 2020-07-27 | 2022-06-01 | 瑞典商阿斯特捷利康公司 | 用達格列淨治療慢性腎臟病之方法 |
WO2022208172A1 (en) | 2021-04-01 | 2022-10-06 | Astrazeneca Uk Limited | Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition |
WO2023144722A1 (en) | 2022-01-26 | 2023-08-03 | Astrazeneca Ab | Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US651003A (en) * | 1899-10-12 | 1900-06-05 | Solomon W Bates | Bicycle-pump. |
JPH0253573A (ja) * | 1988-08-11 | 1990-02-22 | Nippon Riki Kk | ラチェットレンチの製造法 |
US5731299A (en) * | 1992-05-29 | 1998-03-24 | The Procter & Gamble Company | Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
CA2102591C (en) * | 1992-11-12 | 2000-12-26 | Kenji Tsujihara | Hypoglycemic agent |
US5731292A (en) * | 1992-11-12 | 1998-03-24 | Tanabe Seiyaku Co., Ltd. | Dihydrochalcone derivatives which are hypoglycemic agents |
JP2906978B2 (ja) * | 1993-02-25 | 1999-06-21 | 田辺製薬株式会社 | 血糖降下剤 |
US6046222A (en) * | 1993-09-15 | 2000-04-04 | Warner-Lambert Company | Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus |
US5830873A (en) * | 1994-05-11 | 1998-11-03 | Tanabe Seiyaku Co., Ltd. | Propiophenone derivative and a process for preparing the same |
JP2847695B2 (ja) * | 1994-05-11 | 1999-01-20 | 田辺製薬株式会社 | 血糖降下剤 |
BR9610624A (pt) | 1995-09-18 | 1999-03-16 | Ligand Pharm Inc | Tratamento de dmndi com agonistas de de rxr |
JP3065235B2 (ja) | 1995-11-07 | 2000-07-17 | 田辺製薬株式会社 | プロピオフェノン誘導体およびその製法 |
JP3059088B2 (ja) * | 1995-11-07 | 2000-07-04 | 田辺製薬株式会社 | プロピオフェノン誘導体およびその製法 |
US5732199A (en) * | 1996-09-25 | 1998-03-24 | Behavior Tech Computer Corporation | Control method and device of scanner with built-in plug-and-play printer port |
JP3055135B2 (ja) * | 1996-12-26 | 2000-06-26 | 田辺製薬株式会社 | プロピオフェノン誘導体及びその製法 |
DK0850948T3 (da) * | 1996-12-26 | 2002-07-29 | Tanabe Seiyaku Co | Propiophenonderivater og fremgangsmåde til fremstilling deraf |
US6153632A (en) * | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
WO1998057635A1 (en) | 1997-06-18 | 1998-12-23 | Smithkline Beecham Plc | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor |
JP2000080041A (ja) | 1998-03-09 | 2000-03-21 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
TWI249401B (en) | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
DE60022207T2 (de) * | 1999-08-31 | 2006-06-22 | Incyte San Diego Incorporated, San Diego | Benzyliden-thiazolidindione und analoga und ihre verwendung zur behandlung von diabetes |
ATE264337T1 (de) | 1999-08-31 | 2004-04-15 | Kissei Pharmaceutical | Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung |
PE20010580A1 (es) | 1999-09-03 | 2001-05-25 | Takeda Chemical Industries Ltd | Composicion farmaceutica para tratar la diabetes |
JP2001192375A (ja) * | 1999-10-29 | 2001-07-17 | Takeda Chem Ind Ltd | オキシイミノアルカン酸誘導体の結晶 |
AR031078A1 (es) * | 1999-10-29 | 2003-09-10 | Takeda Pharmaceutical | Compuesto acido (e)-4-[4-(5-metil-2-fenil-4-oxalilmetoxi)benziloxiimino]-4-fenilbutirico cristalino, composicion farmaceutica que lo comprende y su uso para fabricar esta ultima. |
JP3723071B2 (ja) * | 1999-11-10 | 2005-12-07 | 武田薬品工業株式会社 | 含窒素5員複素環化合物 |
US6555519B2 (en) | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
EP1333887B1 (de) * | 2000-10-30 | 2006-08-02 | Ortho-McNeil Pharmaceutical, Inc. | Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln |
EP1354888B1 (de) * | 2000-12-28 | 2009-05-20 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln |
CN100577175C (zh) * | 2001-04-04 | 2010-01-06 | 奥索-麦克尼尔药品公司 | 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法 |
-
2002
- 2002-04-03 EP EP02715273A patent/EP1392326B1/de not_active Expired - Lifetime
- 2002-04-03 ES ES02715273T patent/ES2331561T3/es not_active Expired - Lifetime
- 2002-04-03 AT AT02715273T patent/ATE442148T1/de not_active IP Right Cessation
- 2002-04-03 CA CA2443325A patent/CA2443325C/en not_active Expired - Lifetime
- 2002-04-03 CN CNB02810482XA patent/CN100384430C/zh not_active Expired - Lifetime
- 2002-04-03 DE DE60233655T patent/DE60233655D1/de not_active Expired - Lifetime
- 2002-04-03 JP JP2002578974A patent/JP4590158B2/ja not_active Expired - Fee Related
- 2002-04-03 WO PCT/US2002/010542 patent/WO2002080935A1/en active Application Filing
- 2002-04-03 US US10/115,725 patent/US6838442B2/en not_active Expired - Lifetime
- 2002-04-04 TW TW091106917A patent/TWI345978B/zh not_active IP Right Cessation
- 2002-04-04 MY MYPI20021222A patent/MY148432A/en unknown
-
2003
- 2003-02-24 US US10/372,517 patent/US20030195235A1/en not_active Abandoned
-
2007
- 2007-10-24 US US11/923,187 patent/US8183213B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20030195235A1 (en) | 2003-10-16 |
CA2443325C (en) | 2011-06-14 |
JP4590158B2 (ja) | 2010-12-01 |
CN1511038A (zh) | 2004-07-07 |
EP1392326B1 (de) | 2009-09-09 |
WO2002080935A1 (en) | 2002-10-17 |
US8183213B2 (en) | 2012-05-22 |
EP1392326A1 (de) | 2004-03-03 |
JP2004529914A (ja) | 2004-09-30 |
US20030055091A1 (en) | 2003-03-20 |
ES2331561T3 (es) | 2010-01-08 |
CA2443325A1 (en) | 2002-10-17 |
CN100384430C (zh) | 2008-04-30 |
US6838442B2 (en) | 2005-01-04 |
DE60233655D1 (de) | 2009-10-22 |
MY148432A (en) | 2013-04-30 |
TWI345978B (en) | 2011-08-01 |
US20090075864A1 (en) | 2009-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE442148T1 (de) | Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren | |
ATE423559T1 (de) | Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren | |
PT1333887E (pt) | Metodo de tratamento de desordens musculares | |
RS20060320A (en) | Substituted indazole-o-glucosides | |
MY142777A (en) | Substituted indole-o-glucosides | |
MY151032A (en) | Treatment of tnf? related disorders | |
UA86042C2 (en) | Substituted indazole-o-glucosides | |
NO20053042L (no) | Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi. | |
NO20050607L (no) | Fremgangsmate og innretning for tildeling av CO | |
DK1651161T3 (da) | Farmaceutiske præparater og fremgangsmåder til at fremme sårheling | |
PL371736A1 (en) | Method for administering glp-1 molecules | |
ATE413386T1 (de) | Ppar-gamma modulatoren | |
BRPI0515518A (pt) | análogos de loxapina e métodos de usos dos mesmos | |
CY1109238T1 (el) | Δισκιο περιεχον σετιριζινη και ψευδοεφεδρινη | |
MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
NO20045554L (no) | Fremgangsmate for behandling av diabetes | |
DE60212143D1 (de) | Verwendung von thrombin-peptidderivaten zur behandlung von chronischen hautulcera | |
PT1051187E (pt) | Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt) | |
AU2003234425A1 (en) | Methods for therapeutic treatment of carpal tunnel syndrome | |
CY1110368T1 (el) | Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη | |
DK1530462T3 (da) | 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens | |
MXPA04000272A (es) | Derivados de 4-aminociclohexanol sustituidos. | |
NO20045344L (no) | Kombinasjon for behandling av luftveisforstyrrelser | |
NO20033401D0 (no) | Kjemiske forbindelser | |
AU2013204147B2 (en) | Treatment of TNFalpha related disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |